BidaskClub upgraded shares of Concert Pharmaceuticals (NASDAQ:CNCE) from a hold rating to a buy rating in a research report released on Friday morning.

Several other analysts have also recently weighed in on CNCE. Zacks Investment Research cut shares of Concert Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, January 30th. HC Wainwright reaffirmed a buy rating and issued a $21.00 target price on shares of Concert Pharmaceuticals in a report on Friday, October 20th. Stifel Nicolaus reaffirmed a buy rating and issued a $30.00 target price on shares of Concert Pharmaceuticals in a report on Sunday, October 22nd. Mizuho reaffirmed a hold rating and issued a $23.00 target price on shares of Concert Pharmaceuticals in a report on Thursday, February 1st. Finally, ValuEngine raised shares of Concert Pharmaceuticals from a sell rating to a hold rating in a report on Friday, February 2nd. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $24.33.

Concert Pharmaceuticals (NASDAQ:CNCE) opened at $20.09 on Friday. Concert Pharmaceuticals has a 12 month low of $9.01 and a 12 month high of $30.71. The company has a market cap of $457.51, a P/E ratio of 5.40 and a beta of 1.23.

Concert Pharmaceuticals (NASDAQ:CNCE) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.70) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by ($0.16). Concert Pharmaceuticals had a net margin of 62.31% and a negative return on equity of 51.48%. analysts anticipate that Concert Pharmaceuticals will post 4.1 earnings per share for the current fiscal year.

In related news, Director Richard Aldrich sold 31,236 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $19.14, for a total value of $597,857.04. Following the sale, the director now owns 286,975 shares of the company’s stock, valued at $5,492,701.50. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Ronald W. Barrett sold 14,156 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $24.70, for a total transaction of $349,653.20. Following the sale, the director now directly owns 3,539 shares in the company, valued at approximately $87,413.30. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,433,248 shares of company stock worth $37,226,329. 10.10% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC acquired a new stake in Concert Pharmaceuticals during the third quarter worth approximately $153,000. Alliancebernstein L.P. acquired a new stake in Concert Pharmaceuticals during the second quarter worth approximately $174,000. Princeton Capital Management Inc. acquired a new stake in Concert Pharmaceuticals during the third quarter worth approximately $215,000. The Manufacturers Life Insurance Company raised its holdings in Concert Pharmaceuticals by 1.9% during the second quarter. The Manufacturers Life Insurance Company now owns 15,052 shares of the biotechnology company’s stock worth $210,000 after purchasing an additional 287 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC raised its holdings in Concert Pharmaceuticals by 213.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 15,650 shares of the biotechnology company’s stock worth $404,000 after purchasing an additional 10,650 shares in the last quarter. 67.20% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://theolympiareport.com/2018/02/12/bidaskclub-upgrades-concert-pharmaceuticals-cnce-to-buy.html.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.